{
    "clinical_study": {
        "@rank": "144745", 
        "acronym": "LY01609", 
        "arm_group": [
            {
                "arm_group_label": "Vincristine Sulfate Liposome", 
                "arm_group_type": "Experimental", 
                "description": "Vincristine Sulfate For Injection simulation agent 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection: 1.4mg/m2, (2mg, maximum dose), iv, d1, d8, d15, d22.\nDuration between these two agents should be more than 2.5h, and saline should be avoided for flushing before Vincristine Sulfate Liposome For Injection."
            }, 
            {
                "arm_group_label": "Vincristine Sulfate", 
                "arm_group_type": "Active Comparator", 
                "description": "Vincristine Sulfate For Injection 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection simulation agent: 1.4mg/m2,(2mg, maximum dose), iv, d1, 8, 15, 22.\nDuration between these two agents should be more than 2.5h, and saline should not be used for flushing before Vincristine Sulfate Liposome For Injection simulation agent."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether vincristine sulfate liposome could reduce\n      less peripheral neuropathy than vincristine sulfate,and be as effective as vincristine\n      sulfate in adults with Na\u00efve Acute Lymphoblastic Leukemia."
        }, 
        "brief_title": "Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Na\u00efve Acute Lymphoblastic Leukemia", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Adult Acute Lymphoblastic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  De novo untreated ALL patients diagnosed by the bone marrow morphology,\n             immunophenotype.\n\n          -  65 \u2265 Age (years) \u2265 18 , male or female,\n\n          -  ECOG Performance status of 0, 1, or 2.\n\n          -  Patients must fulfill the following laboratory values\n\n               1. Total bilirubin \u22642 ULN (corrected for same age)\n\n               2. AST and ALT  \u22643 ULN ( corrected for same ages)\n\n               3. Serum creatinine \u22642 ULN (corrected for same age)\n\n          -  Didn't receive any of the following treatments within 4 weeks before inclusion:\n             chemotherapy, radiotherapy, replacement therapy, operation, long term of\n             glucocorticoid therapy\uff08>5 days\uff09.\n\n          -  No neurological disorders, no nerve or muscle injury (motor and sensory nerve).\n\n          -  Patient must sign the informed consent and obey the protocol.\n\n        Exclusion Criteria:\n\n          -  Atopy or allergic to multiple medicines or excipients.\n\n          -  With serious complications that affect compliance.\n\n          -  Serious organ dysfunctions or central nervous system disorders.\n\n          -  Mixed phenotype acute leukemia, (T-B).\n\n          -  Burkitt lymphoma/leukemia.\n\n          -  Suspected or confirmed central nervous system leukemia.\n\n          -  Diabetes.\n\n          -  Received antifungal treatment with triazole agents within 1 month before inclusion.\n\n          -  Reliance of antipyretic and analgesic medicines or psychotropic medicines.\n\n          -  Undergoing or has undergone other clinical trials in 4 weeks before inclusion.\n\n          -  Pregnant women, women of breast feeding or childbearing potential without\n             contraception.\n\n          -  Psychological disorders that affect signing consent.\n\n          -  The investigators believe that patients who are not suitable for inclusion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "480", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072785", 
            "org_study_id": "LUYESIKE-VSL-\u2162-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vincristine Sulfate Liposome", 
                "intervention_name": "Vincristine Sulfate Liposome", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vincristine Sulfate", 
                "intervention_name": "Vincristine Sulfate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Vincristine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Adult Acute Lymphoblastic Leukemia", 
            "Vincristine Sulfate Liposome", 
            "Vincristine Sulfate"
        ], 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "contact": {
                "last_name": "Yingchang MI, Doctor"
            }, 
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "zip": "300020"
                }, 
                "name": "Hospital of Blood Diseases, Chinese Academy of Medical Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III Study of Vincristine Sulfate Liposome Or Vincristine Sulfate For Injection Combined Chemotherapy as Initial Induction Regimen In Adults Acute Lymphoblastic Leukemia", 
        "overall_contact": {
            "last_name": "Yingchang Mi, Doctor", 
            "phone": "86-10-22-23909999"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "ORR=CR+CRi CR(Complete response)\nNo circulating blasts or extramedullary disease, No lymphadenopathy,splenomegaly,skin/gum infiltration/testicular mass/CNS involvement\nTrilineage hematopoiesis(TLH)and <5% blast in bone marrow\nANC>1000/microl\nPlatelets>100,000/microl\nCRi(Complete response with incomplete recovery of counts) Recovery of platelets but<100,000 or ANC is <1000/microl", 
                "measure": "Overall response rate(objectives (ORR)", 
                "safety_issue": "No", 
                "time_frame": "up to 35 days"
            }, 
            {
                "description": "Chemotherapy-induced peripheral neuropathy was evaluated By Total Neuropathy Score clinical Version(TNSc).\nIf the score of any item of TNSc at anytime after the start of induction chemotherapy is higher than the baseline,it is considered that peripheral neuropathy occurs.", 
                "measure": "Incidence of General peripheral neuropathy", 
                "safety_issue": "Yes", 
                "time_frame": "A week before enrollment. one,two,three and four weeks after the start of induction chemotherapy"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072785"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Nanjing Luye Sike Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Ethics Committee of Blood Diseases Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Guangdong General Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Qilu Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Xijing Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Xinqiao Hospital Third Miltary University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "China Medical University, China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Sichuan University of West China Hospital GCP Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Second Affiliated Hospital of Xi'an Jiaotong University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Second Hospital of Hebei Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The First Affiliated Hospital of Zhengzhou University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Nanfang Hospital of Southern Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "First Affiliated Hospital of Harbin Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Xuzhou Medical College", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "First Affiliated Hospital of Zhejiang University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Nanjing Luye Sike Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}